Insulet Corp PODD
We take great care to ensure that the data presented and summarized in this overview for INSULET CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PODD
View all-
Vanguard Group Inc Valley Forge, PA8.8MShares$2.93 Billion0.04% of portfolio
-
Black Rock Inc. New York, NY6.06MShares$2.02 Billion0.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.55MShares$1.51 Billion0.28% of portfolio
-
State Street Corp Boston, MA3.09MShares$1.03 Billion0.03% of portfolio
-
Baillie Gifford & CO2.09MShares$696 Million0.5% of portfolio
-
Geode Capital Management, LLC Boston, MA1.97MShares$654 Million0.04% of portfolio
-
Clearbridge Investments, LLC New York, NY1.47MShares$488 Million0.36% of portfolio
-
American Century Companies Inc Kansas City, MO1.41MShares$468 Million0.23% of portfolio
-
Invesco Ltd. Atlanta, GA1.34MShares$446 Million0.07% of portfolio
-
Morgan Stanley New York, NY1.27MShares$422 Million0.02% of portfolio
Latest Institutional Activity in PODD
Top Purchases
Top Sells
About PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Insider Transactions at PODD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 02
2026
|
Laetitia Cousin SVP, Reg, Quality & Compliance |
SELL
Payment of exercise price or tax liability
|
Direct |
140
-3.6%
|
$39,480
$282.92 P/Share
|
|
Dec 31
2025
|
Robert Luther Huffines Director |
BUY
Grant, award, or other acquisition
|
Direct |
50
+8.67%
|
$14,200
$284.24 P/Share
|
|
Dec 15
2025
|
Wayne A.I. Frederick Director |
SELL
Open market or private sale
|
Direct |
1,851
-46.17%
|
$542,343
$293.09 P/Share
|
|
Dec 05
2025
|
Timothy C. Stonesifer Director |
BUY
Open market or private purchase
|
Direct |
962
+17.32%
|
$299,182
$311.73 P/Share
|
|
Oct 31
2025
|
Robert Luther Huffines Director |
BUY
Grant, award, or other acquisition
|
Direct |
477
+50.0%
|
-
|
|
Oct 01
2025
|
Flavia Pease EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
11,708
+43.29%
|
-
|
|
Sep 08
2025
|
Laetitia Cousin SVP, Reg, Quality & Compliance |
SELL
Open market or private sale
|
Direct |
797
-17.0%
|
$277,356
$348.81 P/Share
|
|
Sep 08
2025
|
Laetitia Cousin SVP, Reg, Quality & Compliance |
BUY
Exercise of conversion of derivative security
|
Direct |
797
+8.03%
|
$176,137
$221.48 P/Share
|
|
Sep 08
2025
|
Prem Singh SVP, Global Operations |
SELL
Open market or private sale
|
Direct |
687
-16.58%
|
$238,389
$347.49 P/Share
|
|
Aug 21
2025
|
Eric Benjamin EVP, CPXO |
SELL
Open market or private sale
|
Direct |
4,263
-20.3%
|
$1,415,316
$332.23 P/Share
|
|
Aug 21
2025
|
Michael R Minogue Director |
BUY
Bona fide gift
|
Indirect |
1,380
+8.2%
|
-
|
|
Aug 21
2025
|
Michael R Minogue Director |
SELL
Bona fide gift
|
Direct |
1,380
-63.95%
|
-
|
|
Aug 19
2025
|
Michael R Minogue Director |
BUY
Bona fide gift
|
Indirect |
9,459
+40.2%
|
-
|
|
Aug 19
2025
|
Michael R Minogue Director |
SELL
Bona fide gift
|
Direct |
9,459
-81.42%
|
-
|
|
Aug 19
2025
|
Michael R Minogue Director |
BUY
Bona fide gift
|
Direct |
9,459
+44.88%
|
-
|
|
Aug 19
2025
|
Michael R Minogue Director |
SELL
Bona fide gift
|
Indirect |
9,459
-100.0%
|
-
|
|
Aug 07
2025
|
Prem Singh SVP, Global Operations |
SELL
Open market or private sale
|
Direct |
1,343
-24.48%
|
$429,760
$320.0 P/Share
|
|
Aug 07
2025
|
Prem Singh SVP, Global Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
1,343
+11.58%
|
$362,610
$270.52 P/Share
|
|
Aug 01
2025
|
Lisa Blair Davis SVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,477
+50.0%
|
-
|
|
Jun 13
2025
|
Dan Manea SVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
1,300
-12.51%
|
$390,000
$300.05 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 106K shares |
|---|---|
| Bona fide gift | 20.3K shares |
| Exercise of conversion of derivative security | 27.1K shares |
| Open market or private purchase | 962 shares |
| Bona fide gift | 20.3K shares |
|---|---|
| Open market or private sale | 40.8K shares |
| Payment of exercise price or tax liability | 36.5K shares |